Abstract: Curcumin, one of the most studied chemopreventive agents, is a natural compound extracted from Curcuma longa L. Extensive research over the last half century has revealed that curcumin can inhibit the proliferation of various tumor cells in culture, prevent carcinogen induced cancers in rodents and inhibit the growth of human tumors in xenotransplant or orthotransplant animal models. Several phase I and phase II clinical trials indicated that curcumin is quite safe and may exhibit therapeutic efficacy. The utility of curcumin is limited by its lack of water solubility and relatively low in vivo bioavailability. Multiple approaches including nanoparticles, liposomes, micelles and phospholipid complexes are being sought to overcome these limitations. This review describes the general properties of curcumin and its potential effect against cancer including evidences of its antitumor action in vitro, in vivo, clinically and the strategies to overcome its low bioavailability.
INTRODUCTION
Curcumin, a dietary phytochemical, was first isolated in 1815 from the dried rhizomes of plant Turmeric (Curcuma longa) [1] . Turmeric has been widely used in indigenous medicine to treat a variety of inflammatory conditions and other diseases [2] . Its medicinal properties have been attributed mainly to the curcuminoids, of which curcumin was generally considered to be the most active constituent, other curcuminoids found in tumeric include curcumin -. Fig (1) . Curcumin has been in use for its medicinal benefits since centuries but the first documented case of its use as a drug emerged only in 1937 when it was utilized to treat biliary disease. Since then its therapeutic potential has been explored in inflammatory diseases, neoplastic disease, cardiovascular and neurodegenerative disease, diabetes, cystic fibrosis and other disorders [3] [4] [5] [6] . Majority of the studies suggested that the biological effects of curcumin are mainly derived from its ability to bind directly to various proteins such as cyclooxygenase-2 (COX-2), lipoxygenase, GSK3b and several other regulatory enzymes as well as the ability to modulate intracellular redox state [7, 8] .
Numerous research teams have provided evidence that even low levels of physiologically achievable concentrations of curcumin may be sufficient for its chemopreventive and chemotherapeutic activity. Curcumin has been shown to exhibit therapeutic potential against variety of different cancers including leukemia and lymphoma; gastrointestinal cancers, genitourinary cancers, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, melanoma, neurological cancers and sarcoma [9] . Furthermore, it is considered to be a safe phytochemical without having any significant toxic, genotoxic, and teratogenic properties [5] . Therefore, curcumin has achieved the potential therapeutic interest to cure immune related, metabolic diseases and cancer. Recently, several clinical studies have been initiated to test the activity of curcumin against a range of cancers and other disorders [10] .
*Address correspondence to this author at the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, P. R. China; Tel/Fax: +86-25-83592672; E-mail: zhuhl@nju.edu.cn has very poor bioavailability, its cellular uptake is slow and it gets metabolized very fast once inside the cell [10, 11] . Therefore it requires repetitive oral doses in order to achieve significant concentration inside the cells for any physiological effects. Previous studies indicated that orally administered curcuminoids were absorbed from the alimentary tract and present in the general blood circulation after largely being metabolized to dihydrocurcumin, tetrahydrocurcumin, hexahydrocurcumin and various forms of glucuronide and glucuronide conjugates [12] Fig. (2) . The pharmacokinetic and bioavailability studies of curcumin revealed its poor absorption and rapid elimination from the body. Therefore, curcumin has not yet been approved as a therapeutic agent, in spite of its safety and efficacy in humans. Fortunately, many methods have been developed to enhance the bioavailability and biological activity of curcumin. These strategies include nanoparticles, liposomes, micelles and phospholipid complexes etc. All formulations mentioned are designed primarily to increase absorption of curcumin into tissues. For example, nanoparticles can provide more penetration to membrane barriers because of their small size. Their potential for modification for targeting specific organs also makes them excellent drug carriers. Liposomes, micelles, and phospholipids complexes can reduce the hydrophobicity of curcumin and increase the permeability of membrane barriers by interacting with the membrane components [13] . Recently it was also reported that the water solubility of curcumin could be 12-fold increase by the use of heat [14] .
ANTI-CANCER ACTIVITY OF CURCUMIN
Extensive studies have found that curcumin has a dose dependent chemopreventive effect on a wide array of cancer cell types in vitro, including cells from cancers of the bladder, breast, lung, pancreas, prostate, cervix, head and neck, ovary, kidney, brain, bone marrow, and skin, which has been summarized extensively by Aggarwal et al. [data before 2008, 9] . In vitro and in vivo studies demonstrated curcumin's ability to inhibit carcinogenesis at three stages: tumor promotion, angiogenesis and tumor growth. The molecular basis of anti-carcinogenic and chemopreventive effects of curcumin is attributed to its effect on several targets including transcription factors, growth regulators, adhesion molecules, apoptotic genes, angiogenesis regulators and cellular signaling molecules [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . In addition, curcumin has been shown to suppress the mutagenic effects of capsaicin, tobacco, cigarette smoke condensate, 2-AAF, benzo(a)pyrene,12-dimethyl-be-nz[a] anthracene (DMBA), and aflatoxinB1 [26] [27] [28] . Heterocyclic amines, a group of major mutagens, are produced during broiling, frying, barbequing, heat processing and pyrolysis. They have been shown to be potent carcinogens in rodents, inducing tumors of various organs. Curcumin has been shown to suppress mutagenicity induced by various different classes of cooked food-derived heterocyclic amines [29] . In Table 1 , we summarized the newest progress regarding the antitumor activity in vitro and the mechanism of curcumin in recent years.
Recently, the effects of curcumin on cell proliferation and the induction of apoptosis in human bladder cancer cell lines and intravesical activity in a rat bladder tumor model were studied [64] . Suppresses proliferation and invasion PAK1 activity and cyclin D1 expression
Causes superoxide anion production and p53-independent apoptosis Induction of apoptosis, down-regulation of VEGF and MMP-2/9
Inhibited the activity of SERCA2
Suppressing the phosphorylation of 4E-BP1, eIF4G, eIF4B, and Mnk1, eIF4E and Mnk1
Triggers apoptosis, inhibits the Shh pathway [55] [56] [57] [58] [59] [60] [61] [62] [63] Results showed that curcumin resulted in the induction of apoptotic cell death and caused cells to arrest in the G2/M phase. The antiapoptotic Bcl-2 and Survivin protein was downregulated by the curcumin treatment together with enhancement of the Bax and p53 expression. Moreover, the in vivo study revealed curcumin did induce apoptosis in situ, inhibit and slow the development of bladder cancer. Milacic et al. report that the tumor cellular proteasome is an important target of curcumin [65] . Inhibition of proteasome activity by curcumin in human colon cancer HCT-116 and SW480 cell lines leads to accumulation of ubiquitinated proteins and several proteasome target proteins, and subsequent induction of apoptosis. Furthermore, treatment of HCT-116 colon tumor-bearing ICR SCID mice with curcumin resulted in decreased tumor growth, associated with proteasome inhibition, proliferation suppression, and apoptosis induction in tumor tissues. The effect of curcumin on the growth of human glioma U-87 cells xenografted into athymic mice was also investigated [66] . The results demonstrated that curcumin can cross the blood-brain barrier to a high level and suppresses tumor growth of gliomas in xenograft models. The mechanisms of the anti-tumor effects of curcumin were related partly to the inhibition of glioma-induced angiogenesis through decreasing the gelatinolytic activities of matrix metalloproteinase-9. Jakob et al. evaluated the chemotherapeutic effect of curcumin on glioma cells in vitro and in vivo using an immunocompetent orthotopic mouse model [67] . In vitro, curcumin inhibited JAK1,2/STAT3 tyrosine-phosphorylation in a dose-dependent fashion in murine glioma cell lines. In vivo, curcumin intake reduced the growth and midline crossing of intracranially implanted tumors and proliferation of tumor cells ensuing in significant long-term survival compared with control diet. The results showed that curcumin is capable of suppressing malignant glioma growth in vitro and in vivo. Sun et al. showed curcumin can concentration-dependent inhibit the growth of adenoid cystic carcinoma (ACC) cells via induction of apoptosis [60] . The ability of ACC cells to migrate/invade and induce angiogenesis was also significantly attenuated by curcumin, accompanied by the down-regulation of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-2 and -9. Moreover, curcumin effectively prevented the in vivo growth and angiogenesis of ACC xenografts in nude mice. To evaluate the effect of dietary curcumin on the severity of repeated colitis-associated colorectal cancer, Six-week-old C57BL/6 mice were randomized into two dietary groups: standard diet and curcumin at 0.6% diet [68] . The mice were exposed to 15 cycles of 0.7% dextran sodium sulfate for 1 wk followed by distilled water for 10 days. Results demonstrated the protective/preventive effect of curcumin in the progression of colorectal cancer associated to colitis, which was correlated with a lowered immunoreactivity of ss-catenin, a non-modification of p53 expression, a reduction of proinflammatory cytokine levels and a decrease of inflammatory protein overexpression. Clark et al. firstly demonstrated that curcumin inhibits the adverse effects of nicotine by blocking nicotine-induced activation of the AKT/MTOR pathway in HNSCC, which retards cell migration [69] . Curcumin was highly effective at suppressing growth of SCC40 xenografts and its activity is associated with modulation of MTOR's downstream target pS6. Curcumin at 15 mg significantly increased survival in the 4NQO carcinogenic model survival study. A major cause of lethal progression of HNSCC is local regional migration and invasion of malignant cells, and curcumin significantly inhibited cancer cell migration and invasion in vitro and in vivo where downregulation of pS6 was associated with a significant decrease in MMP-9. To investigate the underlying mechanism by which curcumin inhibits tumor growth and reduces vasculogenic mimicry (VM) in a murine choroidal melanoma model [70] . Sixty mice were given subretinal injection with B16F10 cells and divided into a treatment and a control group. Curcumin was administered to the treatment group once a day at a dose of 100 mg/kg for 18 days starting at d3 (the day of inoculation is designated as d0); an equivalent volume of poloxamer-F68 was administered to the control group. Results indicated that the tumor vol. is reduced (p = 0.000) and the expression levels of EphA2, PI3K, MMP-2 and -9 are also lower in the treatment group than in the control group (p = 0.001). Similarly, mRNA levels in the treatment group are lower than those in the control group (p = 0.000). These data showed curcumin has the ability to inhibit the growth of engrafted melanoma VM channels through the regulation of vasculogenic factors that could be related to the downregulation of the EphA2/PI3K/MMPs signaling pathway. Taiwan, where patients with preneoplastic lesions received up to 12 g curcumin daily, apparently without ill effect and with indications of efficacy in terms of delay of progression to full-blown malignancy, even though the pharmacodynamic arm of the study was not properly controlled [71] . Several groups summarized some of the completed, ongoing, and suspended clinical trials of curcumin dealing with different types of cancer conditions, of which several clinical results have been available [72] [73] [74] . In some of the clinical studies described above, plasma levels of curcumin were measured, and its systemic bioavailability was found to be very low. Metabolism, predominantly via glucuronidation and reduction, was abundant.
CLINICAL RESEARCH
Recently, in a phase II clinical trial Carroll et al. assessed pre-and posttreatment concentrations of PGE and 5-HETE by liquid chromatography tandem mass spectroscopy in ACF and normal-tissue biopsies; ACF number via rectal endoscopy; proliferation by Ki-67 immunohistochemistry; and curcumin concentrations by high-performance liquid chromatography in serum and rectal mucosal samples [75] . Forty-one patients completed the study, neither dose of curcumin reduced PGE or 5-HETE within ACF or normal mucosa or reduced Ki-67 in normal mucosa. A significant 40% reduction in ACF number occurred with the 4-g dose (P < 0.005), whereas ACF were not reduced in the 2-g group (2 g per day for 30 days). The ACF reduction in the 4-g group (4 g per day for 30 days) was associated with a significant, five-fold increase in posttreatment plasma curcumin/conjugate levels (versus pretreatment; P = 0.009). Overall, Curcumin was well tolerated at both 2 g and 4 g and can decrease ACF number.
To determine the effect of curcumin on plasma cells and osteoclasts in patients with MGUS, twenty-six patients with MGUS were recruited and administered 4 g/day oral curcumin [76] . Results showed that oral curcumin is able to decrease paraprotein load in a select group (i.e., those having a paraprotein level of >20 g/L) of patients with MGUS. Fifty percent (5 of 10) of these patients had a 12% to 30% reduction in their paraprotein levels, while on curcumin therapy. In addition, 27% of patients on curcumin had a >25% decrease in urinary N-telopeptide of type I collagen.
In a phase II Trial of curcumin the clinical biological effects of curcumin against advanced pancreatic cancer was evaluated [77] . Patients received 8 g curcumin by mouth daily until disease progression. Serum cytokine levels for interleukin (IL)-6, IL-8, IL-10, and IL-1 receptor antagonists and peripheral blood mononuclear cell expression of NF-B and cyclooxygenase-2 were monitored. Twenty-five patients were enrolled, with 21 evaluable for response. Circulating curcumin was detectable as drug in glucuronide and sulfate conjugate forms, albeit at low steady-state levels, suggesting poor oral bioavailability. Two patients showed clinical biological activity. One had ongoing stable disease for >18 mo; interestingly, one additional patient had a brief, but marked, tumor regression (73%) accompanied by significant increases (4-to 35-fold) in serum cytokine levels (IL-6, IL-8, IL-10, and IL-1 receptor antagonists). No toxicities were observed. Whereas there was considerable interpatient variation in plasma curcumin levels, drug levels peaked at 22 to 41 ng/mL and remained relatively consistent. over the first 4 wk. In summary, oral curcumin is well tolerated and, despite its limited absorption, has clinical biological in some patients with pancreatic cancer.
All these preclinical data lead to various, but still scarce, clinical studies (some on-going). The gap between basic research and clinical application is still growing. The results published until now have shown that the treatment is safe and provide some positive clues of curcumin as a chemo-preventive agent. The design of randomized clinical trials should also consider the likelihood of individuals in the non-curcumin arm of the trial consuming turmeric or curcumin of their own volition. Another problem that needs to be clear in future studies is the exact therapeutic dose and the preventive dose for various cancers. Although curcumin's low systemic bioavailability after oral dosing may limit access of sufficient concentrations for pharmacologic effects in tissues, novel delivery methods are in preclinical development to overcome this barrier. The intriguing finding that curcumin metabolites may be a suitable avenue for observational studies could help to lay the groundwork for a full randomized controlled clinical trial. Overall, more data from the completed and ongoing clinical studies of curcumin are needed, which it is hoped will be reported soon to further address the question of whether curcumin is an effective chemopreventive agent in humans.
FORMULATIONS
Considering the poor aqueous solubility and low bioavailability of curcumin several strategies have been evaluated to enhance the biological activity of curcumin, which were sumarried extensively by Anand and the co-workers [13] . These strategies include nanoparticles, liposomes, micelles, and phospholipid complexes. These formulations are designed primarily to increase absorption of curcumin into tissues. Nanoparticles can provide better penetration to membrane barriers because of their small size. Liposomes, micelles, and phospholipids complexes can reduce the hydrophobicity of curcumin; these carriers also can increase the permeability of membrane barriers by interacting with the membrane components.
Recently, to increase the solubility and targeted delivery, a water-soluable polyethylene glycol (PEG)-conjugated curcumin system was generated, in which curcumin is covalently linked to PEG35kD [78] . PEGylated curcumin showed much greater reduction of cell growth than free curcumin in pancreatic cancer cells. Cells treated with PEGylated curcumin had increased arrest at the mitotic phase with the formation of abnormal multinucleated cells, indicating that this compound affects cell cycle progression, which may contribute to cell growth inhibition. PEGylated curcumin also increased protein stability of these proteins in pancreatic cancer cells and directly inhibited the activity of Jab1/CSN-associated kinases. The results suggest that PEGylated curcumin inhibits cell proliferation through suppression of Jab1/CSN activity. More importantly, PEGylated curcumin sensitized pancreatic cancer cells to gemcitabine-induced apoptosis and cell proliferation inhibitory effects. Collectively, the PEGylated curcumin conjugate has much more potent effects on pancreatic cancer cell growth inhibition than free curcumin. Anand et al. employed a polymer-based nanoparticle approach to improve bioavailability [79] . Curcumin was encapsulated with 97.5% efficiency in biodegradable nanoparticulate formulation based on poly (lactide-co-glycolide) (PLGA) and a stabilizer polyethylene glycol (PEG)-5000. In vitro curcumin (NP) exhibited very rapid and more efficient cellular uptake than curcumin.
Esterase staining revealed that curcumin (NP) was at least as potent as or more potent than curcumin in inducing apoptosis of leukemic cells and in suppressing proliferation of various tumor cell lines. In mice, curcumin (NP) was more bioavailable and had a longer halflife than curcumin. These results showed that curcumin-loaded PLGA nanoparticles formulation has enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo over curcumin. A biodegradable and biocompatible polymer, poly (D,L-lactide-co-glycolide) was used to fabricate curcumin microparticles [80] . When injected in mice, a single dose of microparticles sustained curcumin levels in the blood and other tissues for nearly a month. Curcumin levels in the lungs and brain, frequent sites of breast cancer metastases, were significantly higher than that in the blood. Further, curcumin microparticles showed marked anticancer efficacy in nude mice bearing MDA-MB-231 xenografts compared with other controls. Repeated systemic injections of curcumin were not effective in inhibiting tumor growth. Treatment with curcumin microparticles resulted in diminished vascular endothelial growth factor expression and poorly developed tumor microvessels, indicating a significant effect on tumor angiogenesis. These results suggest that sustained delivery of chemopreventives such as curcumin using polymeric microparticles is a promising new approach to cancer chemoprevention and therapy.
Mohanty et al. have synthesized curcumin loaded nanoparticulate delivery system which encapsulate curcumin within glycerol monooleate based nanoparticle (GMO NP). [81] . Unlike free curcumin, it is readily dispersed in aqueous medium, showing narrow size distribution ~192 nm ranges (as observed by microscope) with biocompatibility. Furthermore, it displayed enhanced stability in phosphate buffer saline by protecting encapsulated curcumin against hydrolysis and biotransformation. Most importantly, nanoparticulate curcumin was comparatively more effective than native curcumin against different cancer cell lines under in vitro condition with time due to enhanced cellular uptake resulting in reduction of cell viability by inducing apoptosis. In mice, nanoparticulate curcumin was more bioavailable and had a longer half-life than native curcumin as revealed from pharmacokinetics study. A polymeric nanoparticle encapsulated curcumin formulation (NanoCurc) showed remarkably higher systemic bioavailability in plasma and tissues compared with free curcumin upon parenteral administration [82] . In xenograft models of human pancreatic cancer established in athymic mice, administration of parenteral NanoCurc significantly inhibits primary tumor growth. The combination of parenteral NanoCurc with gemcitabine results in enhanced tumor growth inhibition, suggesting an additive therapeutic influence in vivo. Furthermore, this combination completely abrogates systemic metastases in orthotopic pancreatic cancer xenograft models. A novel cyclodextrin complex of curcumin (CDC) developed and examined for anti-inflammatory and antiproliferative effects [83] . CDC was found more active than free curcumin in inhibiting TNF-induced activation of the inflammatory transcription factor NF-B and in suppressing gene products regulated by NF-B, including those involved in cell proliferation (cyclin D1), invasion (MMP-9), and angiogenesis (VEGF). CDC was also more active than free curcumin in inducing the death receptors DR4 and DR5. Antiproliferative assays also demonstrated that CDC was more active than free curcumin in suppressing proliferation of various cancer cell lines. In addition, compared with free curcumin, CDC had a greater cellular uptake and longer half-life in the cells. To assess the potential of new copolymeric micelles to modify the pharmacokinetics and tissue distribution of Curcumin (CUR), a poly (D,L-lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(D, L-lactide-co-glycolide) (PLGA-PEG-PLGA) copolymer was synthesized [84] . The pharmacokinetics and biodistribution of CURloaded micelles in vivo were evaluated. The biodistribution study in mice showed that the micelles decreased drug uptake by liver and spleen and enhanced drug distribution in lung and brain. These results suggested that PLGA-PEG-PLGA micelles would be a potential carrier for CUR. Curcumin-loaded solid lipid nanoparticles (C-SLNs) was produced by using a micro-emulsification technique [85] . The in vitro release was predominantly by diffusion phenomenon and was prolonged up to 7 days. In vivo pharmacokinetics performed after oral administration of C-SLNs (50, 25, 12.5 and 1 mg/kg dose) and (free) solubilized curcumin (C-S; 50 mg/kg), using a validated LC-MS/MS method in rat plasma revealed significant improvement (at p<0.05) in BA (39 times at 50 mg/kg; 155 times at 1 mg/kg; and, 59 and 32 times at 12.5 and 25 mg/kg, respectively) after administration of C-SLNs at all the doses with respect to C-S.
Curcumin was incorporated in egg-phosphatidylcholine (EPC) liposomes at a drug to lipid molar ratio 1:14 achieving high incorporation efficiency close to 85% [86] . The liposomal curcumin was lyophilized preserving thus its stability. The reconstitution of the formulation resulted in the original liposomal suspension. The release in FBS showed a plateau near 14% at 96 h of incubation. The in vitro studies against colorectal cancer cell lines have shown that liposomes improve the activity of curcumin and the liposomal formulation found to be more potent against HCT116 and HCT15, cell lines which express the MDR phenotype. Lim et al. used nanoparticleencapsulated curcumin to treat medulloblastoma and glioblastoma cells [87] . This formulation caused a dose-dependent decrease in growth of multiple brain tumor cell cultures, including the embryonal tumor derived lines DAOY and D283Med, and the glioblastoma neurosphere lines HSR-GBM1 and JHH-GBM14. Downregulation of the insulin-like growth factor pathway in DAOY medulloblastoma cells was observed, providing one possible mechanism for the changes. Levels of STAT3 were also attenuated. In addition, encapsulation of curcumin in MPEG-PCL micelles can improve the t1/2 and AUC of curcumin in vivo [88] . As well as free curcumin, Cur/MPEG-PCL micelles efficiently inhibited the angiogenesis on transgenic zebrafish model. In an alginateencapsulated cancer cell assay, i.v. application of Cur/MPEG-PCL micelles more efficiently inhibited the tumor cell-induced angiogenesis in vivo than that of free curcumin. I.v. application of Cur/MPEG-PCL micelle (25 mg kg-1 curcumin) inhibited the growth of s.c. C-26 colon carcinoma in vivo (p < 0.01), and induced a stronger anticancer effect than that of free curcumin (p < 0.05).
Even though many experiments to evaluate various properties of curcumin's formulations have been encouraging, most studies have been done in vitro. And these novel preparations have been subjected to very few animal studies. Whether these formulations have the same molecular targets as curcumin is also not clear at present. Thus neither the bioavailability nor their activity in animal models is known. Future studies are expected to unravel curcumin formulations that would be more suitable for human clinical trials.
FUTURE PROSPECTS
All above published observations suggest that curcumin affects numerous pathways linked with tumorigenesis and thus has potential both for prevention and treatment of cancer. Furthermore, it is considered to be a safe antitumor agent without having any significant toxic, genotoxic, and teratogenic properties. However, the limited bioavailability may be a problem, and more clinical trials with curcumin either alone or in combination with existing therapies are also needed to fully appreciate its potential. Formulation of curcumin may hold promise in the future. Although curcumin's low systemic bioavailability after oral dosing may limit access of sufficient concentrations for pharmacologic effects in tissues outside the gastrointestinal tract, novel delivery methods are in preclinical development to overcome this barrier. In summary, its safety combined with its low cost, and multiple targeting potential makes curcumin or the formulations as ideal agents to be explored for prevention and treatment of various cancers. 
